Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. The company’s marketed vaccines include 13-valent pneumococcal polysaccharide conjugate vaccine, varicella vaccine, freeze-dried, hepatitis B vaccine, inflammatory vaccine, 23-valent pneumococcal polysaccharide vaccine, DTAP/HIB combined vaccine, diphtheria, tetanus and acellular pertussis combined vaccine, adsorbed, rabies vaccine (human diploid cell) for human use, hib conjugate vaccine, measles and rubella combined vaccine, sars-cov-2 vaccine, inactivated, and covid-19 vaccine. Its research and development vaccines comprise measles, mumps and rubella vaccine, 2DTAP- HIB-IPV, 4-valent influenza (split), poliomyelitis vaccine (vero cells), and inactivated, sabin strain. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
Metrics to compare | 300601 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300601PeersSector | |
---|---|---|---|---|
P/E Ratio | 247.0x | 44.9x | −0.7x | |
PEG Ratio | −2.85 | 0.28 | 0.00 | |
Price/Book | 1.9x | 2.2x | 2.6x | |
Price / LTM Sales | 6.4x | 9.5x | 3.4x | |
Upside (Analyst Target) | 15.4% | 24.3% | 39.1% | |
Fair Value Upside | Unlock | 7.7% | 5.3% | Unlock |